

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/21651975>

The endo-8,9-epoxide of aflatoxin B₁: A new metabolite

ARTICLE *in* CHEMICAL RESEARCH IN TOXICOLOGY · MAY 1992

Impact Factor: 3.53 · DOI: 10.1021/tx00027a002 · Source: PubMed

READS

42

4 AUTHORS, INCLUDING:



Thomas Harris

Vanderbilt University

331 PUBLICATIONS 8,818 CITATIONS

SEE PROFILE

Communications

The *endo*-8,9-Epoxy of Aflatoxin B₁: A New Metabolite

Kevin D. Raney,^{†,‡} Brian Coles,[§] F. Peter Guengerich,^{†,||} and Thomas M. Harris^{*,†,‡}

Departments of Chemistry and Biochemistry and Center in Molecular Toxicology, Vanderbilt University, Nashville, Tennessee 37235, and Cancer Research Campaign Molecular Toxicology Group, University College and Middlesex School of Medicine, London W1P 6DB, U.K.

Received January 6, 1992

AFB₁¹ (1) is a highly toxic fungal metabolite which has been shown to be a carcinogen in animals and implicated by epidemiological studies as a carcinogen in man (1). Genotoxicity has been ascribed to an unstable metabolite formed by oxidative metabolism (2). The intermediate has never been isolated from biological systems, but interception by reaction with DNA and with glutathione points to the biologically relevant species being the *exo*-8,9-epoxide (3) (3-5). The epoxide eluded synthesis for many years due to its high reactivity; however, we recently reported a procedure for its preparation (6). The method uses dimethyldioxirane (2) as the oxidant and gives high yields of crystalline epoxide. Reactivity of the *exo*-epoxide appears to be generally concordant with the properties of the fugitive, bioactivated AFB₁.

In the earlier report we stated that the dimethyldioxirane epoxidation procedure was stereospecific for formation of the *exo*-epoxide. On closer examination of the reaction we now find that the *endo*-epoxide (4) is also formed, although to a much smaller extent. Herein, we report the synthesis and characterization of AFB₁ *endo*-8,9-epoxide and its formation by rat and human liver microsomes.

Experimental Procedures

Chemicals. AFB₁ was purchased from Aldrich Chemical Co. (Milwaukee, WI). Dimethyldioxirane was synthesized as described by Murray and Jeyaraman (7) and Adam et al. (8). Solutions of dioxirane were stored over anhydrous MgSO₄ at -20 °C and were used within 1 month of preparation. ¹H NMR spectra were obtained on a Bruker (Billerica, MA) AM-400 instrument.

Synthesis of AFB₁ *exo*- and *endo*-8,9-Epoxydes. AFB₁ (3 mg) was treated with 1.5 equiv of dimethyldioxirane (6). After 20 min, the solvent and excess dioxirane were evaporated under a stream of N₂. The resulting solid was dissolved in [2H₆]acetone, and the ¹H NMR spectrum was obtained. The principal product was the *exo*-8,9-epoxide (3). Close examination of the spectrum revealed a second species, *endo*-AFB₁ 8,9-epoxide (4), which was produced in ~10% yield and was the only other product detected.

Recrystallization. The mixture of *exo*- and *endo*-AFB₁ epoxides was dissolved in 300 μL of CH₂Cl₂. Anhydrous acetone (300 μL) was added, and the solution was stored at -20 °C for 24 h to produce crystals. The supernatant was removed from the crystals with a syringe. The crystals were washed with a small amount of anhydrous acetone and dried with N₂. The supernatant was evaporated under a stream of N₂. ¹H NMR spectra were obtained on the crystals and the residue from the supernatant.

The crystals were found to be pure *exo*-AFB₁ epoxide. Integration of the signals in the spectrum of material obtained from the supernatant revealed a 4:1 mixture of *exo*- and *endo*-epoxides. Additional *exo*-epoxide was removed from the supernatant by crystallization from a smaller volume of a CH₂Cl₂/acetone mixture; the ¹H NMR spectrum of the resulting supernatant indicated a 2:1 mixture of *exo*- and *endo*-epoxides. Decoupling experiments were performed on this sample to assist in assigning the ¹H NMR spectrum of 3 (Table I).

Microsomal Incubations. Incubation mixtures (250-μL total volume) contained human or rat liver microsomes (3 mg/mL), 100 mM sodium phosphate buffer (pH 7.4), an NADPH generating system (containing final concentrations of 5 mM glucose 6-phosphate, 1 mM NADP⁺, and 1 IU/mL yeast glucose-6-phosphate dehydrogenase), 5 mM GSH, mouse or rat liver cytosol (3 mg/mL), and 50 μM AFB₁. Incubations were carried out for 40 min at 37 °C, and reactions were quenched by addition of 50 μL of 2 M CH₃CO₂H. Product mixtures were stored at -20 °C. Samples were thawed, centrifuged, and then analyzed by reverse-phase HPLC using an Econosphere octadecylsilane (5 μm, 4.6-mm × 250-mm) column (Alltech Associates, Deerfield, IL). Elution solvents consisted of (A) 20 mM aqueous CH₃CO₂NH₄ (pH 4.0) and (B) a mixture of CH₃OH/CH₃CN (1:1 v/v). A multistep gradient of 90% A and 10% B (v/v) to 80% A and 20% B (v/v) over 20 min increasing to 50% A and 50% B (v/v) at 35 min was used to elute AFB₁ metabolites. Retention times of the GSH conjugate of AFB₁ *exo*-epoxide, the GSH conjugate of AFB₁ *endo*-epoxide, AFQ₁, and AFB₁ were 21.0, 21.8, 30.7, and 36.0 min, respectively. UV absorbance of metabolites was monitored at 360 nm with a single-wavelength detector. Peak areas were estimated using a Hitachi D-2500 Chromato-Integrator with AFB₁ 8,9-dihydrodiol serving as an external standard (9, 10).

Preparation of Authentic Samples of the GSH Conjugates of AFB₁ *exo*- and *endo*-Epoxides. GSH (200 mg, 0.065 mmol) in 2 mL of CH₃OH was treated with 50 mg of Na metal (2.2 mmol), causing the GSH to dissolve immediately. AFB₁ epoxide (1.5 mg, 2:1 *exo*:*endo* in 0.75 mL of CH₂Cl₂) was added. The solution immediately became yellow and after 1 min was neutralized with ~1.5 mL of 1 M aqueous CH₃CO₂H. After evaporation in vacuo with a Speed Vac concentrator (Savant Instruments, Inc., Hicksville, NY), the residue was dissolved in 4 mL of H₂O and clarified using a 0.4-μm filter. Purification by HPLC (vide supra) gave 70% and 50% yields, respectively, of the conjugates of the *exo*- and *endo*-epoxides as determined by HPLC peak areas in the chromatogram. The products were distinguished by comparison with the adduct derived from pure *exo*-epoxide. The structure of the adduct derived from *endo*-epoxide has been established by NMR spectroscopy and by comparison with adducts of ethanethiol (K. D. Raney, unpublished results).

Results and Discussion

Synthesis of *exo*- and *endo*-AFB₁ Epoxides. Epoxidation of 1 using freshly prepared dimethyldioxirane (2) in anhydrous acetone gives a ~10:1 mixture of the

* Address correspondence to this author at the Department of Chemistry and Center in Molecular Toxicology, Vanderbilt University, Nashville, TN 37235.

[†] Department of Chemistry, Vanderbilt University.

[‡] Center in Molecular Toxicology, Vanderbilt University.

[§] University College and Middlesex School.

^{||} Department of Biochemistry, Vanderbilt University.

¹ Abbreviations: AFB₁, aflatoxin B₁; AFQ₁, aflatoxin Q₁; GSH, reduced L-glutathione.





Figure 1. ^1H NMR spectrum of a $\sim 10:1$ mixture of AFB_1 *exo*- and *endo*-epoxides arising from epoxidation of AFB_1 with dimethyldioxirane.

Scheme I. Formation of AFB_1 *exo*- and *endo*-Epoxides



epoxides 3 and 4 (Scheme I). No other products are observed if the reaction is carried out under anhydrous conditions. The downfield region of the ^1H NMR spectrum of this mixture of epoxides is shown in Figure 1 with the resonances of the *endo* isomer enlarged for clarity. The *exo*-epoxide can be crystallized from the mixture using CH_2Cl_2 /acetone (1:1 v/v). Final traces of *endo*-epoxide could be removed from the crystals by washing with dry acetone. ^1H NMR analysis of the crystallization supernatant showed a 2:1 mixture of *exo*- and *endo*-epoxides. Procedures are presently being developed for complete purification of the *endo*-epoxide to facilitate studies of its chemistry and biology.

^1H NMR Studies. The doublet at δ 6.81 (Figure 1) was assigned to H-6a on the basis of chemical shift and by comparison with the corresponding signal in the *exo*-epoxide (6). Irradiation of the δ 6.81 signal led to collapse of the doublet of doublets at δ 4.29 to a doublet permitting assignment of the latter signal as H-9a. The doublet at δ 5.67 ($J = 1.7$ Hz) was assigned at H-8; H-8 of the *exo*-epoxide also appears as a doublet and has a similar coupling constant (δ 5.50, $J = 1.8$ Hz). Irradiation at δ 5.67 led to collapse of the incompletely resolved doublet of doublets at δ 4.14 into a doublet establishing the peak at δ 4.14 as arising from H-9. The vicinal relationship of H-9 and H-9a was confirmed by irradiating H-9 (δ 4.14) and observing collapse of the H-9a doublet of doublets (δ 4.29) to a doublet. Other assignments of the *endo*-epoxide were made by comparison with the *exo*-epoxide isomer (Table I). The conclusion that the major isomer is the *exo*-epoxide and the minor one the *endo* is consistent with the greater steric hindrance of the *endo* face of the 8,9 double bond. A key difference in the spectra of the two stereoisomers is the coupling between H-9 and H-9a. The trans protons in the *exo* isomer have a torsional angle near 90° and are not coupled to each other, whereas the angle between the cis protons in the *endo* isomer is small, leading

Table I. ^1H NMR Assignments for AFB_1 *exo*- and *endo*-Epoxides^a

proton	AFB_1 <i>exo</i> -epoxide, δ	AFB_1 <i>endo</i> -epoxide, δ
2,2'	2.53, 2 H, m	2.53 (overlapped with <i>exo</i> 2,2')
3,3'	3.44, 2 H, m	3.44 (overlapped with <i>exo</i> 3,3')
4-OCH ₃	4.07, 3 H, s	4.05, 3 H, s
5	6.66, 1 H, s	6.54, 1 H, s
6a	6.22, 1 H, d	6.81, 1 H, d
8	5.50, 1 H, d	5.67, 1 H, d
9	4.03, 1 H, d	4.14, 1 H, dd ^b
9a	4.55, 1 H, d	4.29, 1 H, dd
coupling constants	AFB_1 <i>exo</i> -epoxide, Hz	AFB_1 <i>endo</i> -epoxide, Hz
$J_{8,9}$	1.8	1.7
$J_{9,9a}$	~ 0	2.6
$J_{9a,6a}$	5.8	6.6

^a Spectra were obtained in CD_2Cl_2 . ^b Incompletely resolved.

to a coupling constant of 2.6 Hz.

Microsomal Incubations. It is noteworthy that metabolic activation by hepatic microsomes also yields a mixture of the *exo*- and *endo*-epoxides. Although the epoxides cannot be detected directly in the microsomal oxidation, the GSH adducts can be trapped by carrying out oxidations in the presence of GSH transferases. The GSH conjugates were identified by comparison with authentic samples prepared by reaction of the epoxide mixture with the anion of GST.

The *exo*-epoxide is efficiently trapped as the GSH conjugates by mouse α class GSH *S*-transferase enzymes (11) and can therefore be analyzed by HPLC as the GSH conjugate (5, 12). On the other hand, constitutive rat GSH *S*-transferase enzymes conjugate the *exo*-epoxide inefficiently. We find the reverse to be true for the *endo*-epoxide; it is readily trapped as its GSH conjugate by rat GSH *S*-transferase enzymes but not by mouse; thus with the rat transferase the enzymatic formation of AFB_1 *endo*-epoxide can be assayed by monitoring formation of the GSH adduct.

AFB_1 was incubated with human or rat liver microsomes using mouse cytosol or rat cytosol to trap *exo*- and *endo*-epoxides, respectively. Estimates of rates of production of AFB_1 *endo*-epoxide by three samples of human microsomes and two of rat are presented in Table II. HPLC chromatograms resulting from incubation of human liver microsomes in the presence of mouse and rat cytosol are shown in panels A and B, respectively, of Figure 2. With the human microsomes, the GSH conjugates of both epoxides are observed. The previously described adduct of the *exo*-epoxide is the predominant form produced (5). With rat microsomes only low levels of the *endo*-epoxide are trapped as the GSH adduct. We are presently inves-

Table II. Production of AFB₁ *exo*- and *endo*-Epoxides by Rat and Human Liver Microsomes

microsomal sample	pmol of AFB ₁ epoxide-GSH conjugate formed min ⁻¹ (mg of protein) ⁻¹	
	<i>exo</i> -ep- oxide- GSH ^a	<i>endo</i> -ep- oxide-GSH ^b
human 107	34	12.3
human 110	41	4.6
human 115	40	2.0
rat (untreated)	32	0.9
rat (phenobarbital-induced)	68	0.8

^a 8,9-Dihydro-8-(S-glutathionyl)-9-hydroxy-AFB₁ arising from AFB₁ *exo*-epoxide (5). ^b Stereoisomer of 8,9-dihydro-8-(S-glutathionyl)-9-hydroxy-AFB₁ arising from AFB₁ *endo*-epoxide.




Figure 2. HPLC chromatograms resulting from incubation of AFB₁ with human microsomes in the presence of GSH and GSH S-transferase enzymes. All labeled peaks were identified by cochromatography with standards. (A) Human liver 107 microsomes with mouse liver cytosol as the source of GSH S-transferases (50-μL injection). (B) Human liver 107 microsomes with rat liver cytosol as the source of GSH S-transferases (80-μL injection).

tigating the abilities of individual P-450s and other enzymes to form these stereoisomeric epoxides and the abilities of various GSH S-transferase enzymes to conjugate them.

Incomplete stereospecificity of epoxidation of AFB₁ by dimethyldioxirane and by microsomes is certainly not unique. We find that *m*-chloroperbenzoic acid also gives stereoisomeric mixtures.²

Conclusions

Although the *endo*-epoxide appears to be only a minor product in chemical and enzymatic epoxidations of AFB₁, its genotoxicity and other biological activity may have disproportionate significance. Our earlier studies with epoxides of AFB₁ and related species have shown that the ratio of mutations to adducts produced is relatively constant (10); however, there is substantial precedent with the polycyclic aromatic hydrocarbons for a dramatic influence of epoxide stereochemistry on the types of adducts formed and on the subsequent biological activity (13, 14).

Preliminary evidence suggests that the *endo*-epoxide is less susceptible than the *exo* to hydrolytic conversion to

8,9-dihydrodiol. Consequently, the *endo*-epoxide may have a longer lifetime in biological milieu and increased opportunity to react with critical targets. We have not yet examined the reactivity of the *endo*-epoxide with DNA, but the formation and biological disposition of adduct(s) of the *endo*-epoxide may be different.

References

- (1) Busby, W. F., and Wogan, G. N. (1984) Aflatoxins. In *Chemical Carcinogens* (Searle, C. E., Ed.) pp 945-1136, American Chemical Society, Washington, DC.
- (2) Garner, R. C., Miller, E. C., and Miller, J. A. (1972) Liver microsomal metabolism of aflatoxin B₁ to a reactive derivative toxic to *Salmonella typhimurium* TA 1530. *Cancer Res.* **32**, 2058-2066.
- (3) Lin, J. K., Miller, J. A., and Miller, E. C. (1977) 2,3-Dihydro-2-(guan-7-yl)-3-hydroxy-aflatoxin B₁, a major acid hydrolysis product of aflatoxin B₁-DNA or -ribosomal RNA adducts formed in hepatic microsome-mediated reactions and in rat liver in vivo. *Cancer Res.* **37**, 4430-4438.
- (4) Essigmann, J. M., Croy, R. G., Nadzan, A. M., Busby, W. F., Jr., Reinhold, V. N., Büchi, G., and Wogan, G. N. (1977) Structural identification of the major DNA adduct formed by aflatoxin B₁ in vitro. *Proc. Natl. Acad. Sci. U.S.A.* **74**, 1870-1874.
- (5) Moss, E. J., Judah, D. J., Przybylski, M., and Neal, G. E. (1983) Some mass-spectral and n.m.r. analytical studies of a glutathione conjugate of aflatoxin B₁. *Biochem. J.* **210**, 227-233.
- (6) Baertschi, S. W., Raney, K. D., Stone, M. P., and Harris, T. M. (1988) Preparation of the 8,9-epoxide of the mycotoxin aflatoxin B₁: the ultimate carcinogenic species. *J. Am. Chem. Soc.* **110**, 7929-7931.
- (7) Murray, R. W., and Jeyaraman, R. (1985) Dioxiranes: Synthesis and reactions of methyldioxiranes. *J. Org. Chem.* **50**, 2847-2853.
- (8) Adam, W., Chan, Y.-Y., Cremer, D., Gauss, J., Scheutzw, D., and Schindler, M. (1987) Spectral and chemical properties of dimethyldioxirane as determined by experiment and ab initio calculations. *J. Org. Chem.* **52**, 2800-2803.
- (9) Baertschi, S. W., Raney, K. D., Shimada, T., Harris, T. M. and Guengerich, F. P. (1989) Comparison of rates of enzymatic oxidation of aflatoxin B₁, aflatoxin G₁, and sterigmatocystin and activities of the epoxides in forming guanyl-N⁷ adducts and inducing different genetic responses. *Chem. Res. Toxicol.* **2**, 114-122.
- (10) Raney, K. D., Shimada, T., Kim, D.-H., Groopman, J. D., Harris, T. M., and Guengerich, F. P. (1992) Oxidation of aflatoxins and sterigmatocystin by human liver microsomes: significance of aflatoxin Q₁ as a detoxication product of aflatoxin B₁. *Chem. Res. Toxicol.* **5**, 202-210.
- (11) Ramsdell, H. S., and Eaton, D. L. (1990) Mouse liver glutathione S-transferase isoenzyme activity toward aflatoxin B₁-8,9-epoxide and benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide. *Toxicol. Appl. Pharmacol.* **105**, 216-225.
- (12) Coles, B., Meyer, D. J., Ketterer, B., Stanton, C. A., and Garner, R. C. (1985) Studies on the detoxication of microsomally activated aflatoxin B₁ by glutathione and glutathione transferases in vitro. *Carcinogenesis* **6**, 693-697.
- (13) Lehr, R. E., Kumar, S., Levin, W., Wood, A. W., Chang, R. L., Conney, A. H., Yagi, H., Sayer, J. M., and Jerina, D. M. (1985) The bay region theory of polycyclic aromatic hydrocarbon carcinogenesis. In *Polycyclic Hydrocarbons and Carcinogenesis* (Harvey, R. G., Ed.) pp 63-84, American Chemical Society, Washington, DC.
- (14) Dipple, A., Moschel, R. C., and Bigger, C. A. H. (1984) Polynuclear aromatic carcinogens. In *Chemical Carcinogens* (Searle, C. E., Ed.) ACS Monograph 182, pp 41-163, American Chemical Society, Washington, DC.

² R. Iyer and T. M. Harris, unpublished observations.